Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, Michael H Belmont, Maria Laura Bertolaccini, D Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesús, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-García, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K Leaf, Nina Kello, Jason S Knight, Carl Laskin, Alfred I Lee, Kimberly Legault, Steve R Levine, Roger A Levy, Maarten Limper, Michael D Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V Seshan, Savino Sciascia, Maria G Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cécile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan
OBJECTIVE: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. METHODS: This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators' consensus as the gold standard...
August 28, 2023: Annals of the Rheumatic Diseases